Transplantation and cellular therapy
High Exposure of Intravenous Alemtuzumab Is Associated with Increased Risk of Double-Stranded DNA Viral Infections in Patients with Non-Malignant Disease Undergoing Allogeneic HCT.
Transplantation and cellular therapy
Liberalizing Requirements for Hospital Proximity Post-CD19 CAR for Children with Low Burden B-ALL at Infusion.
Transplantation and cellular therapy
Younger Children Have Increased Mixed Myeloid Chimerism with Busulfan-Based Conditioning for Hematopoietic Cell Transplantation of Non-Malignant Disease.
Transplantation and cellular therapy
Younger Children with Non-Malignant Disease Have Increased Incidence of Mixed Myeloid Chimerism After Allogeneic Hematopoietic Cell Transplantation with Busulfan-Based Conditioning.
Transplantation and cellular therapy
High Melphalan Exposure Increases the Risk of Graft-versus-Host Disease in Pediatric Patients Undergoing Alpha-Beta T-Cell Depleted Haploidentical Transplantation.
Transplantation and cellular therapy
A Randomized Clinical Trial Evaluating Lactiplantibacillus Plantarum for the Prevention of GI aGvHD: A Report From the Children's Oncology Group (ACCL1633).
Transplantation and cellular therapy
Fludarabine Pharmacokinetic Model-Based Dosing Minimizes the Risk of Graft Rejection in Pediatric Patients Undergoing Allogeneic Hematopoietic Cell Transplantation.
Transplantation and cellular therapy
The Relationship Between Busulfan Exposure and Achievement of Sustained Donor Myeloid Chimerism in Patients with Non-Malignant Disorders.
Transplantation and cellular therapy
Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year.
Transplantation and cellular therapy